Correction of Experimental Hypertensive Neuroretinopathy with Semax


  • Sofia S. Chernyaeva



Semax; Hypertensive Neuroretinopathy; Rats; Laser Doppler Flowmetry; Electroretinography..


Currently, the search for ways of specific pharmacological correction of hypertensive retinal changes is of great interest. The objective of this
research is to study the correction possibility of retinal injuries with semax in the simulation of hypertensive neuroretinopathy in Wistar rats.
This model was performed by daily injection of N-nitro-L-arginine methyl ester (L-NAME) at a dose of 12.5 mg/kg within 28 days and a single
increase in intraocular pressure (IOP) to 110 mmHg for 5 min. The retinoprotective effect of semax at a dose of 72 μg/kg, in comparison with
picamilon at a dose of 30 mg/kg, was estimated by laser Doppler flowmetry (LDF) and electroretinography (ERG). The use of semax led to
increase in the retinal microcirculation level to 671.7 ± 22.1 perfusion units (p < 0.05, in comparison with the group with picamilon). In the
group with semax, the b/a coefficient increased reliably by 14.6% (p < 0.05) in comparison with the group with picamilon. Thus, semax can
be a promising agent in hypertensive neuroretinopathy treatment.







How to Cite

Correction of Experimental Hypertensive Neuroretinopathy with Semax. (2022). Journal of Pharmaceutical Negative Results, 13(3), 41-45.